Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: A rational and effective means for treating hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 1, 2008, Pages 1-9

  Gojanovic, Boris ^a   Feihl, Franćois ^a   Liaudet, Lucas ^a   Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitors; Anglotensin II; Antagonists; Calcium antagonists; Guidelines; Hypertensin; Tolerability

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN; VERAPAMIL;

ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FLUSHING; HEART PALPITATION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY INJURY; MONOTHERAPY; PATIENT COMPLIANCE; PLASMA HALF LIFE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYMPATHETIC TONE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; HYPERTENSION; INDOLES; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VERAPAMIL;

EID: 42249095978     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2008.007     Document Type: Review

References (67)

1. He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997;81:1077-97.
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
3. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens 2004;22:11-19.
4. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomised trials. Arch Intern Med 2005;165 1410-19.
5. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407.
6. Dickerson CJE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;288:2977-81.
8. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
9. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003;290:2805-16.
10. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31.
11. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005;366:895-906.
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;326:1427-31.
13. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managing Care 2000;9 (suppl.):2-6.
14. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42 1206-52.
15. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
16. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-57.
17. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998;55 509-17.
18. Grossman E, Messerli FH. Calcium antagonists. Progress Cardiovasc Dis 2004;47:34-57.
19. McEwan JR, Fuller RW. Angiotensin converting enzyme inhibitors and cough. J Cardiovasc Pharmacol 1989;13(suppl 3):S67-69.
20. Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Progress Cardiovasc Dis 2006;49:16-25.
21. Williams B. Recent hypertension trials: Implications and controversies. J Am Coll Cardiol 2005;45:813-27.
22. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. JRAAS 2006;7:61-3.
23. Mancia G, Dell'Oro R, Quasrti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens 2006;24 (suppl 1):51-6.
24. Folkow B. Physiological aspects of primary hypertension. Phys Rev 1982;62:347-504.
25. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003;361:1629-41.
26. Beevers DG, Sleight P. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: Is there a risk? BMJ 1996;312:1143-45.
27. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997;80:1453-8.
28. Binggeli C, Corti R, Sudano I, Luscher TF, Noll G. Noll G. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension. Hypertension 2002; 39:892-6.
29. Niarchos AP, Pickering TG, Morganti A, Laragh JH. Plasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man. Clin Exper Hypertens 1982;4 761-89.
30. Seljeflot I, Moan A, Kjeldsen S, Sandvik E, Arnesen H. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996;27:1299-304.
31. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, Ishii M. Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol 1999;26:797-802.
32. Sturani A, Chiarini C, Degliesposti E, Santoro A, Zuccala A, Zucchelli P. Heart rate control in hypertensive patients treated by captopril. Br J Clin Pharmacol 1982;14:849-55.
33. Pancera P, Presciuttini B, Sansone S et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. J Hypertens 1999;17:513-21.
34. Kuschnir E, Acuna E, Sevilla D et al. Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996; 18:1213-24.
35. Karlberg BE, Andrup MAO. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Pressure 2000;9:140-5.
36. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182-7.
37. Pool J, Kaihlanen P, Lewis G et al. Once-daily treatment of patients with hypertension: A placebo-controlled study of amlodipine and benazepril vs. amlodipine or benazepril alone. J Hum Hypertens 2001;15:495-98.
38. Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/ benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002;15:550-6.
39. Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501.
40. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80.
41. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004;17:37-42.
42. Hasebe N, Kikuchi K, NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: The NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005;23:445-53.
43. Luscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993;21:305-09.
44. Letellier P, Overlack A, Agnes E, Desche P. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: A double-blind multicentre study. J Hum Hypertens 1994;8:145-9.
45. de Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: A double-blind, placebo-controlled parallel group study. J Hypertens 1997;15:87-91.
46. Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang wRY. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001;14 567-72.
47. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. Hypertens 2006;24:185-92.
48. Poldermans D, Glazes R, Kargiannis S et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrodhlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-89.
49. Gennari C, Nami R, Pavese G, Gragnani S, Bianchini C, Buracchi P. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther 1989;3(suppl 1):319-25.
50. Messerli FH. Vasodilatory edema: A common side effect of antihypertensive therapy. Curr Cardiol Reports 2002;4:479-82.
51. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001;14:963-8.
52. Fogari R, Zoppi A, Derosa G et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4.
53. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exper Hypertens 1999;21:973-85.
54. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HC1 versus comparable component-based therapy. Congest Heart Fail 2003;9:324-32.
55. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-09.
56. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.
57. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-73.
58. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007; 369:201-07.
59. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7.
60. Bakris GL, Gaxiola E, Messerli FH et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004;44:637-42.
61. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Ttandolapril Study. Hypertension 2007;50:299-305.
62. Cooper-Dehoff R, Cohen JD, Bakris GL et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006;98:890-4.
63. Poulter NR, Wedel H, Dahlof B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13.
64. O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995;26:2-9.
65. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
66. Jamerson KA, Bakris GL, Wun CC et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hyertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801.
67. Jamerson K, Bakris GL, Dahlof B et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Pressure 2007;16:80-6.